Our company

We are a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.

Our strategy

Our organisation

Our business is organised to deliver our strategic priorities sustainably, supporting continued scientific innovation and commercial success. We focus on the discovery, development and commercialisation of prescription medicines in Oncology and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

BioPharmaceuticals

We want to transform healthcare, change the lives of billions of people for the better and address some of the biggest healthcare challenges facing humankind. Our ambition is to stop the progress of these often degenerative, debilitating, and life-threatening conditions, achieve remission, and one day cure them.

Learn more

Oncology

We are leading a revolution in oncology to redefine cancer care. We have a bold ambition to provide cures for cancer in every form. We are following the science to understand cancer and all its complexities to discover, develop and deliver life-changing treatments and increase the potential to save the lives of people around the world.

Learn more

Our purpose and values

Our purpose and values help explain why we exist, what we hope to accomplish, the behaviours we value, how we will achieve our goals, and the promise of our brand to our stakeholders.

We push the boundaries of science to deliver life-changing medicines.

Our purpose underpins everything we do. It gives us a reason to come to work every day. It reminds us why we exist as a company. It helps us deliver benefits to patients and create value for shareholders. It also sets the context for our employees’ activities and the roles of our teams, partners and other collaborators.

We follow the science. We put patients first. We play to win. We do the right thing. We are entrepreneurial.

Our values determine how we work together and the behaviours that are integral to our drive for success. Our values guide our decision making, define our beliefs and foster a strong AstraZeneca culture.

Discover how our Values and behaviours come to life in the work that we do

Our people

Pascal Soriot

Executive Director and Chief Executive Officer

Ezogelin Oflazoglu-Gruyters

Vice-President, Head of External R&D and Strategic Alliances, Oncology R&D

Menelas (Mene) Pangalos

Executive Vice-President, BioPharmaceuticals R&D

Maria Belvisi

Senior Vice President and Head of Research and Early Development, Respiratory, Inflammation and Autoimmunity, BioPharmaceuticals R&D

Helen Angell

Principal Scientist, Oncology, Translational Sciences, IMED Biotech Unit

Paul Harper

Principal Scientist, Discovery Sciences, R&D

Jason Snape

Global Safety, Health and Environment Director and Senior Principal Environmental Scientist
View our people
View our Senior Executive Team
View our board

Sustainability

Access to healthcare

Access to healthcare at AstraZeneca goes beyond our medicines. We provide healthcare solutions along a continuum of care — from prevention, awareness, diagnosis and treatment, to post-treatment and wellness. We work across our main therapy areas to address unmet medical needs and health disparities.

Environmental protection

Climate change is now a climate crisis. The effects of the continued growth of the global economy and its reliance on fossil fuels are putting at risk not only human health, but also the ability of the Earth to sustain life. We are taking action now because we recognise the inextricable link between a healthy planet and healthy people.

Ethics and transparency

We want to be valued for not only our medicines, but also for the way we work. We aim to build trust by demonstrating integrity, transparency and fair treatment in everything that we do. We have committed to ensure racial equity in our workplace and access to our medicines, in our clinical trials and beyond.
See more about Sustainability

Key information

View our pipeline
Annual Report 2020

Partnering brochure

PDF 1,609KB

What science can do

It takes passion, energy and knowledge to enable us to put science at the heart of everything we do. Learn more about our exciting work in stories from our people and partners.

Read more

News & press releases

Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer

  • Corporate Press Release

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

  • Corporate Press Release

First quarter 2021 results

  • Corporate Press Release

Selumetinib recommended for approval in the EU by CHMP as the first medicine for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

  • Corporate Press Release

Tagrisso recommended for approval in the EU by CHMP for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer

  • Corporate Press Release

Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants

  • Corporate Press Release
View all news